Early results of the phase I/II study investigating the all-oral combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in acute Myeloid Leukemia (SAVE)

Real-world treatment patterns among patients With Myelodysplastic Syndromes initiating oral Decitabine and Cedazuridine or intravenous/subcutaneous hypomethylating agents

A phase 2 study of the fully oral combination of ASTX727 (Decitabine/Cedazuridine) plus Venetoclax for older and/or unfit patients with acute Myeloid Leukemia